Search filters

List of works by Mario Sznol

A 71-year-old woman with decreased vision, nyctalopia, and peripheral vision loss

scientific article published on 31 December 2016

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

scientific article published on 15 April 2019

A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer

scientific article

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

scientific article

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

scientific article published on 4 November 2015

A Serum Protein Signature Associated with Outcome After Anti-PD1 Therapy in Metastatic Melanoma.

scientific article published on 5 December 2017

A clinical development paradigm for cancer vaccines and related biologics

scientific article

A novel anti-melanoma SRC-family kinase inhibitor

A phase 2 trial of dasatinib in advanced melanoma ⬇️

scientific article published on November 29, 2010

A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer

scientific article

A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye

scientific article published on 20 July 2007

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

scientific article

Advances in the Treatment of Metastatic Melanoma: New Immunomodulatory Agents ⬇️

scientific article published on April 1, 2012

Advances in the systemic treatment of metastatic melanoma.

scientific article published on May 2013

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer ⬇️

scientific article published on March 1, 2013

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

scientific article published on 30 August 2016

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

scientific article published on 21 May 2020

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

scientific article published on 29 July 2020

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

scientific article published on 31 January 2020

Betting on immunotherapy for melanoma

scientific article published on September 2009

Biology of advanced uveal melanoma and next steps for clinical therapeutics

scientific article

Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy

scientific article published on July 2014

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy ⬇️

scientific article published on December 1, 2011

C-Raf is associated with disease progression and cell proliferation in a subset of melanomas

scientific article published on 08 September 2009

Cancer Immunotherapy: Past Progress and Future Directions

scientific article

Challenges in Conducting Clinical Research on Patients With Advanced Melanoma

scientific article published on January 2017

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

scientific article published on 18 March 2015

Chitinase-like Proteins in Lung Injury, Repair, and Metastasis ⬇️

scientific article published on May 1, 2012

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

scientific article published on 30 January 2018

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies ⬇️

scientific article published on October 1, 2010

Combination Strategies PD-1/PD-L1 Antagonists.

scientific article

Combination immunotherapy: Where do we go from here?

scientific article published on 18 August 2015

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

scientific article

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

scientific article

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

scientific article (publication date: 2 July 2015)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

scientific article published on 8 January 2018

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

scientific article published on 7 November 2016

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management

scientific article

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

scientific article published on 27 July 2015

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

scientific article

Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma

scientific article published on June 2006

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

scientific article published on 15 December 2017

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"

scientific article published on 26 March 2011

Immune Modulation Therapy and Imaging: Workshop Report

scientific article published on 17 August 2017

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

scientific article published on 24 March 2015

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

scientific article published on 11 May 2016

In vitro studies of dasatinib, its targets and predictors of sensitivity ⬇️

scientific article published on April 1, 2011

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

scientific article

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.

scientific article published in April 2014

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

scientific article

Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications

scientific article

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells

scientific article published on 22 December 2016

Introducing a New Series: Immunotherapy Facts and Hopes

scientific article published on 23 February 2018

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial ⬇️

scientific article published on March 27, 2012

Ipilimumab-induced Perforating Colitis ⬇️

scientific article published on October 1, 2013

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial

scientific article published on 08 November 2018

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.

scientific article published on 4 November 2015

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Melanoma brain metastases: is it time to reassess the bias?

scientific article

Melanoma: a model for testing new agents in combination therapies

scientific article

MicroRNA signatures differentiate melanoma subtypes

scientific article

Molecular Markers of Response to Treatment for Melanoma ⬇️

scientific article published on March 1, 2011

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

scientific article published on 17 October 2017

Nivolumab plus ipilimumab in advanced melanoma

scientific article

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

scientific article

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

scientific article

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

scientific article

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

scientific article published on 6 May 2014

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

scientific article published on 7 November 2013

Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers

scientific article

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

scientific article published in December 2003

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion

scientific article published in May 2004

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors ⬇️

scientific article published on September 15, 2003

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

scientific article published on November 2005

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma

scientific article

Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.

scientific article

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies

scientific article

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma

scientific article published on 29 September 2014

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

scientific article published on 20 June 2017

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients ⬇️

scientific article published on October 1, 2003

Plasma Markers for Identifying Patients with Metastatic Melanoma ⬇️

scientific article published on April 12, 2011

Pre-treatment patient selection for nivolumab benefit based on serum mass spectra

scientific article published on 4 November 2015

Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy

scientific article published in April 2015

Programmed death ligand-1 expression in non-small cell lung cancer

scientific article

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

scientific article published on 01 December 2018

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival ⬇️

scientific article published on June 15, 2012

Relative roles of targeted therapies and immunotherapies in melanoma

scientific article published on October 1, 2012

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

scientific article published on December 1, 2010

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

scientific article

Revisiting ribonucleotide reductase as a target to enhance radiation and chemotherapy anti-tumor activity

scientific article published on July 2003

Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis

scientific article published on 15 December 2014

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

scientific article published on 14 November 2016

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer ⬇️

scientific article published on June 2, 2012

Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation

scientific article

The Phoenix Rises: The Rebirth of Cancer Immunotherapy

scientific article published on 17 May 2017

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization

scientific article published on 26 January 2007

Therapeutic combinations of immune-modulating antibodies in melanoma and beyond

scientific article published on 14 February 2015

Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis

scientific article published on 4 November 2015

Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer

scientific article published on July 2008

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome

scientific article published on 14 February 2006

White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy ⬇️

scientific article published on February 15, 2011

Paulina is supported by:

About Paulina

Help